Ocugen (OCGN) News Today $0.68 -0.02 (-2.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.69 +0.01 (+1.18%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Klotho Neurosciences (NASDAQ:KLTO) and Ocugen (NASDAQ:OCGN) Head to Head SurveyFebruary 22 at 1:58 AM | americanbankingnews.comOcugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 21 at 8:00 AM | globenewswire.comWhat is HC Wainwright's Forecast for Ocugen FY2024 Earnings?Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Ocugen in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company wiFebruary 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Ocugen FY2024 Earnings?Ocugen, Inc. (NASDAQ:OCGN - Free Report) - HC Wainwright increased their FY2024 earnings per share estimates for Ocugen in a research note issued on Thursday, February 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.17) per share for the year, up frFebruary 17, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Ocugen (NASDAQ:OCGN) StockFebruary 15, 2025 | americanbankingnews.comOcugen price target raised to $8 from $7 at H.C. WainwrightFebruary 14, 2025 | markets.businessinsider.comOcugen shares rise as H.C. Wainwright lifts price target to $8February 14, 2025 | msn.comWhy Ocugen (OCGN) Is Advancing TodayFebruary 14, 2025 | msn.comOcugen's (OCGN) "Buy" Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $6.00 price target on shares of Ocugen in a report on Thursday.February 13, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Given New $8.00 Price Target at HC WainwrightHC Wainwright upped their price target on shares of Ocugen from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Thursday.February 13, 2025 | marketbeat.comOcugen announces dosing completion in Phase 2 ArMaDa clinical trialFebruary 12, 2025 | markets.businessinsider.comOcugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationFebruary 12, 2025 | globenewswire.comOcugen gets positive EU opinion for ATMP classification for OCU400February 3, 2025 | seekingalpha.comEuropean Commission nods at Ocugen's gene therapyFebruary 3, 2025 | msn.comOcugen Gets Positive Opinion For OCU400 Advanced Therapy Medicinal Product ClassificationFebruary 3, 2025 | markets.businessinsider.comOcugen’s OCU400 granted positive opinion by EMA in retinitis pigmentosaFebruary 3, 2025 | markets.businessinsider.comOcugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis PigmentosaFebruary 3, 2025 | globenewswire.comOcugen files to sell 57.54M shares of common stock for holdersFebruary 1, 2025 | markets.businessinsider.comOcugen announces IND in effect after FDA reviewJanuary 28, 2025 | markets.businessinsider.comOcugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19January 27, 2025 | globenewswire.comOcugen’s Promising Pipeline and Strategic Advancements Bolster Buy RatingJanuary 24, 2025 | markets.businessinsider.comOcugen's (OCGN) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and set a $6.00 target price on shares of Ocugen in a research report on Thursday.January 24, 2025 | marketbeat.comOcugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $6.00 price objective on shares of Ocugen in a report on Thursday.January 23, 2025 | marketbeat.comBreakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical TrialJanuary 18, 2025 | msn.comBreakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaJanuary 17, 2025 | msn.comOcugen announces first patient dosed in Phase 1 OCU200 trial for DMEJanuary 16, 2025 | markets.businessinsider.comOcugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular EdemaJanuary 16, 2025 | globenewswire.comOcugen reports ‘positive’ update from Phase 1/2 OCU400 trialJanuary 13, 2025 | markets.businessinsider.comOcugen’s OCU400: Promising Clinical Efficacy and Strong Buy Rating Amidst Valuation and Safety ConfidenceJanuary 13, 2025 | markets.businessinsider.comOcugen's (OCGN) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Ocugen in a research note on Monday.January 13, 2025 | marketbeat.comOcugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis PigmentosaJanuary 13, 2025 | globenewswire.comOcugen, Inc. (NASDAQ:OCGN) Shares Acquired by State Street CorpState Street Corp lifted its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN - Free Report) by 7.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,824,517 shares of the company's stock after purchasing an additional 1December 25, 2024 | marketbeat.comOcugen’s Gene Therapy Trial for Dry AMD AdvancesDecember 21, 2024 | msn.comOcugen’s Phase 1/2 study of OCU410 approved for continuation by DSMBDecember 19, 2024 | markets.businessinsider.comData and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationDecember 19, 2024 | globenewswire.comOcugen to Present at Oppenheimer Movers in Rare Disease SummitDecember 11, 2024 | msn.comOcugen CEO to Present at Oppenheimer Movers in Rare Disease SummitDecember 11, 2024 | globenewswire.comOcugen Inc. stock rises Friday, still underperforms marketDecember 6, 2024 | marketwatch.comOcugen, Inc. to Present at NobleCon20 Emerging Growth Equity ConferenceDecember 1, 2024 | msn.comOcugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceNovember 28, 2024 | finance.yahoo.comOcugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity ConferenceNovember 27, 2024 | globenewswire.comOcugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease TreatmentNovember 22, 2024 | msn.comOcugen announces EMA granted orphan medicinal product designation for OCU410STNovember 21, 2024 | markets.businessinsider.comOcugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic AtrophyNovember 21, 2024 | msn.comOcugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt DiseaseNovember 20, 2024 | globenewswire.comOcugen reports positive data for OCU400, OCU410November 19, 2024 | msn.comOcugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trialNovember 19, 2024 | markets.businessinsider.comOcugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationNovember 19, 2024 | globenewswire.comOcugen Appoints Ramesh Ramachandran as Financial OfficerNovember 16, 2024 | markets.businessinsider.comWall Street Expects These 2 Under-the-Radar Growth Stocks to OutperformNovember 16, 2024 | msn.com Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address OCGN Media Mentions By Week OCGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼1.240.60▲Average Medical News Sentiment OCGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼75▲OCGN Articles Average Week Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunome News Avadel Pharmaceuticals News CureVac News Avid Bioservices News Nuvation Bio News Prothena News Cronos Group News GH Research News Bicara Therapeutics News Verve Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCGN Stock Alerts